Purple Biotech Expands Research Collaboration in Immuno-Oncology in Combination with NT219

Purple Biotech Ltd. announced the expansion of an existing research agreement, led by Dr. Menashe Bar-Eli at The University of Texas MD Anderson Cancer Center, and will evaluate the potential efficacy of the combination of NT219, a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3, and immuno-oncology drugs, such as anti-CTLA4 or anti-PD1/PDL1 antibodies.